Our group includes 4 professor, 4 associate professor, 1 postdoctoral researcher, 2 research assistants, 4 doctor degree candidates and 25 master degree candidates.

Our research foci are basic researches and clinic translations of animal anti-infective drugs:

(1) The discovery, validation, utilization of novel targets：To explore interaction of pathogen and host, and discover the novel drug targets, and then take high-throughput screening campaigns and related pharmacological and pharmacodynamics assays.

(2) Discovery of novel animal anti-infection chemical entities and their druggablility: We focus on the comprehensive prevention and control of major animal diseases and pet drug innovation, and take natural products such as xanthones and clinically privileged structures such as pyrazine allylhydrazine as the lead compounds, and utilize molecular dynamic simulation and a new generation of artificial intelligence as the guide, and oriented synthesis and chemoenzymatic synthesis as the structural optimization strategies, high-content or high-throughput screening platforms to discover novel anti-infective molecules. The properties and structural characteristics, ADME&T and developability of the drug candidates are studied to solve the common technical problems in the animal drug innovation.

(3) Microbe resistance： By monitoring the drug resistance in the animal breeding, exploring molecule mechanisms of microbe resistance, and developing novel drugs, the scientific and rational use of the animal drugs are provided.